Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Other Non-Current Liabilities (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 47.76% to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2025, down 47.76% year-over-year, with the annual reading at $3.0 million for FY2025, 47.76% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $3.0 million at Gyre Therapeutics, down from $3.2 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $10.8 million in Q3 2024, with the low at $48000.0 in Q1 2024.
  • Average Other Non-Current Liabilities over 3 years is $5.1 million, with a median of $4.6 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities crashed 99.5% in 2024, then soared 2814.58% in 2025.
  • Over 3 years, Other Non-Current Liabilities stood at $4.7 million in 2023, then grew by 20.03% to $5.7 million in 2024, then crashed by 47.76% to $3.0 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $3.0 million, $3.2 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.